FairValu
BETA
JOHNSON & JOHNSON

JOHNSON & JOHNSON

JNJ

Drug Manufacturers - General • Healthcare

Current Price
$234.340.00%
Market Cap
$564.11B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

AI Analysis of JNJ's Strategic Position

Access detailed SWOT, moat analysis, growth sustainability, and risk assessment powered by Vertex AI.

Summary

Multi-agent institutional research for JNJ

Factor Scorecard

Factor scores will populate once the financial statement data finishes loading.

Price Chart

JNJ via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available from current approved sources.

No Data

No annual financial data available.

Analyst Consensus

0 Analysts
Recommendation mix unavailable from the current feed
Buy
-
Hold
-
Sell
-

Coverage count comes from 0 analyst opinions, but the Buy/Hold/Sell mix was not included in the current payload.

Price Target

N/AAverage Target
Low
N/A
Current
$234.34
High
N/A

Peer Comparison

TickerPrice
JNJJOHNSON & JOHNSON
$234.34
Financial data not available for quantitative analysis.
Company News & Profile

Loading latest news...

About the Company

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Next Earnings Date

Jul 15, 2026